CubaPLUS Magazine

The production of the Cuban vaccine Abdala, to combat COVID-19, has already reached the figure of 40 million doses, thanks to the audacious decision to join efforts and resources of two BioCubaFarma companies, reported this Tuesday on its Twitter page the Center for Genetic Engineering and Biotechnology (CIGB).

That figure, the note adds, constitutes a milestone in Cuban science, for the health of the people of this country and of other nations that need it.

This immunogen was the first vaccine in Cuba against Covid-19 and in Latin America, which in its phase III trial demonstrated 100 percent efficacy in preventing severe systemic disease and deaths, according to recent information from its creators.

Abdala is the result of the joint effort of the CIGB and the Food Information and Control Agency (AICA).